Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

Archives of Psychiatry and Psychotherapy is a distinguished journal published by the Polish Society of Psychiatry, focusing on the dynamic fields of clinical psychology and psychiatry. Established in 2001 and continuing through 2024, this journal serves as a platform for the dissemination of significant research findings, theoretical advancements, and practical applications in the realm of mental health. With its ISSN 1509-2046 and E-ISSN 2083-828X, it stands out for its commitment to enhancing the understanding of psychiatric disorders and treatments. While it currently reflects a Q3 ranking in Clinical Psychology and a Q4 ranking in Psychiatry and Mental Health, its growing impact and visibility in academic circles are evident from its Scopus rankings, placing it within the 28th and 24th percentiles of its respective categories. The journal emphasizes open access, promoting equitable access to valuable knowledge for researchers, practitioners, and students alike, thus fostering collaboration and innovation in the field. As the mental health landscape evolves, the Archives of Psychiatry and Psychotherapy remains an essential resource for those dedicated to advancing psychiatric practice and research.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

ACTA NEUROPSYCHIATRICA is a distinguished journal published by Cambridge University Press, covering essential research across the fields of psychiatry and neuroscience. Since its inception in 1989, it has become a pivotal resource for researchers and clinicians, providing a platform for the latest advancements and insights in biological psychiatry. With an impressive Scopus rank of #66 out of 567 in the Psychiatry and Mental Health category, and #10 out of 51 in Biological Psychiatry, the journal is recognized for its significant contributions to the field, boasting an 88th percentile ranking in overall impact. Although it operates under a traditional access model, the journal remains committed to disseminating high-quality research that addresses critical issues in mental health. Whether you are a professional seeking the latest findings or a student aiming to deepen your knowledge, ACTA NEUROPSYCHIATRICA is an indispensable resource for cutting-edge developments that shape our understanding of the human mind.

Current Behavioral Neuroscience Reports, published by SPRINGERNATURE, stands at the forefront of advancements in the intricate field of behavioral neuroscience. Since its inception in 2014, this journal has steadily garnered attention within academic circles, boasting a commendable ranking among its peers, including a Q3 classification in Behavioral Neuroscience and a Q2 classification in Public Health, Environmental and Occupational Health as of 2023. Although it operates under traditional access models, the journal is committed to disseminating high-quality research that bridges the gap between neuroscience and behavioral studies, appealing to researchers, professionals, and students alike. With a notable E-ISSN of 2196-2979, Current Behavioral Neuroscience Reports facilitates valuable insights that are critical for understanding the underlying mechanisms of behavior and their implications for public health and environmental factors. This journal is essential for those seeking to contribute to a multidisciplinary dialogue that enhances our comprehension of behavioral neuroscience.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.